Abstract
No public abstract is available from the verified source records.
Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureUma Purighalla
Abstract
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
unpaywall
Confidence 95%
datacite
Confidence 0%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Once-weekly semaglutide in adults with overweight or obesity
10.1056/nejmoa2032183 · 2021
Tirzepatide once weekly for the treatment of obesity
10.1056/nejmoa2206038 · 2022
Pharmacogenomics of GLP-1 receptor agonists: a genome-wide analysis of observational data and large randomised controlled trials
10.1016/s2213-8587(22)00340-0 · 2023
Unresolved referenced work
Kept as external metadata until matched
GLP-1 receptor agonists in the treatment of type 2 diabetes—State-of-the-art
10.1016/j.molmet.2020.101102 · 2021
The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity
10.1111/dom.14280 · 2021
Effects of liraglutide on gastrointestinal functions and weight in obesity: a randomized clinical and pharmacogenomic trial
10.1002/oby.23481 · 2022
Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity
10.1111/dom.12932 · 2017
Selection of antiobesity medications based on phenotypes enhances weight loss: a pragmatic trial in an obesity clinic
10.1002/oby.23120 · 2021
Development and validation of a patient-assessed gastroparesis symptom severity measure: the Gastroparesis Cardinal Symptom Index
10.1046/j.1365-2036.2003.01612.x · 2003
Gastroparesis
10.1038/s41572-018-0038-z · 2018
No additional external references are available.